NDAINTRAVESICALSOLUTION
Approved
Apr 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CYSTO-CONRAY II (iothalamate meglumine) by Guerbet is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1972.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSTO-CONRAY II is an iodinated contrast media solution containing iothalamate meglumine for intravesical (bladder) instillation. It provides radiographic visualization of the lower urinary tract during retrograde urography by leveraging iodine's high atomic weight for radiopacity. The drug is absorbed minimally (<1%) under normal conditions but may reach 12% systemic absorption with pyelorenal backflow.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30% score) suggests a mature, stable market with potential for smaller team or transition focus.
Mechanism of Action
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CYSTO-CONRAY II offers limited career growth; the product has zero linked job opportunities and faces structural decline due to diagnostic imaging evolution. This role suits professionals in transition, managing mature products, or seeking roles in market access for specialty diagnostics.
Brand Manager
Worked on CYSTO-CONRAY II at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.